Uniject filled with oxytocin can help treat and prevent postpartum hemorrhage.
This web page is a resource for countries and programs considering the introduction of oxytocin in the Uniject™ injection system (Uniject). Included in these resources are some essential pieces of information for planning and decision-making:
- Policy and planning resources
- Technical resources
- Field evaluations
- Online resources
The easy-to-use, injection-ready format of Uniject ensures an accurate dose of oxytocin in a nonreusable, sterile injection system with minimal preparation and minimum waste. The features and benefits of oxytocin in Uniject will help programs launch innovative approaches to expand prevention and treatment of postpartum hemorrhage such as:
- Administration by skilled midwives, auxiliary nurses, or other trained lay providers.
- Use in areas of limited health facility infrastructure and/or health worker shortages.
- Overcoming acceptability concerns, including fear of injections, and safety concerns, regarding reuse of needles.
These benefits can improve the ability of health workers to administer oxytocin in hospital facilities as well as during emergencies or in remote locations.
WHO Statement regarding the use of misoprostol for postpartum haemorrhage prevention and treatment
This statement explains the current WHO position regarding the use of misoprostol for the prevention of postpartum hemorrhage.
Management of the Third Stage of Labor to Prevent Postpartum Hemorrhage: Joint Statement
ICM and FIGO, 2004
This statement provides recommendations on programming as well as specific interventions and procedures for the prevention of PPH. The International Federation for Obstetrics and Gynecology (FIGO) and the International Confederation of Midwives (ICM) are key partners in global efforts to reduce maternal death and disability in the world. Their mission statements share a common commitment in promoting the health, human rights, and well-being of all women, especially those at greatest risk of death and disability associated with childbearing.
- Download/view file in English (129 KB PDF) from the Postpartum Hemorrhage Prevention and Treatment website.
- Download/view file in French (156 KB PDF) from the Postpartum Hemorrhage Prevention and Treatment website.
- Download/view file in Spanish (135 KB PDF) from the Postpartum Hemorrhage Prevention and Treatment website.
Prevention and Treatment of Postpartum Hemorrhage: New Advances for Low Resource Settings: Joint Statement
ICM and FIGO, 2006
This statement summarizes the current status of prevention and treatment of PPH in low-resource settings and provides recommendations for improving the continuum of care. Both ICM and FIGO endorse international recommendations that emphasize the provision of skilled birth attendants and improved obstetric services as central to efforts to reduce maternal and neonatal mortality.
- Download/view file in English (189 KB PDF) from the Postpartum Hemorrhage Prevention and Treatment website.
- Download/view file in French (201 KB PDF) from the Postpartum Hemorrhage Prevention and Treatment website.
- Download/view file in Spanish (195 KB PDF) from the Postpartum Hemorrhage Prevention and Treatment website.
Recommendations on the Prevention of Postpartum Hemorrhage: A Summary of the Results from a WHO Consultation
The World Health Organization (WHO) held a Technical Consultation in Geneva to discuss the various issues related to the prevention of PPH and to develop recommendations. This document highlights key recommendations from the report.
Managing Complications in Pregnancy and Childbirth: A Guide for Midwives and Doctors
The chapter entitled Vaginal Bleeding After Childbirth in this guide provides WHO guidance on managing vaginal bleeding after childbirth, including recommendations for oxytocin administration and dosing.
HealthTech Historical Profile: The Uniject Device
This document provides an overview of PATH’s development and advancement of Uniject.
The Radically Simple Uniject Device
This four-page brochure tells the story of Uniject—how it grew from a concept to an easy-to-use, all-in-one injection system that will be used to vaccinate every newborn in Indonesia against hepatitis B and to help eliminate maternal and neonatal tetanus globally. The publication covers the development, evaluation, licensing, production, and design and function of the Uniject injection system. Photographs and a timeline of Uniject’s history are included.
Introducing TT Uniject in Maternal and Neonatal Tetanus Elimination
This document provides materials to assist health workers and program managers in the introduction, training, and proper use of the tetanus toxoid vaccine in Uniject.
Oxytocin in Uniject
Introducing Oxytocin in the Uniject Device: An Overview for Decision-Makers
This overview has been developed for program planners considering introduction and/or expansion of the use of oxytocin, in particular oxytocin packaged in Uniject, to reduce the incidence of PPH as a component of their maternal and child health programming. Administering oxytocin is just one component of active management of the third stage of labor. Available in English and Spanish.
A HealthTech Reference List: Key References and Resources for the Introduction of Oxytocin in the Uniject™ Device
This compilation contains key references and resources to aid program planners in the introduction of oxytocin in Uniject.
Pilot Introduction of Oxytocin in Uniject® During Active Management of the Third Stage of Labor (AMTSL) at the Institutional Level in Guatemala
This report shares the results of a pilot introduction of oxytocin in Uniject for use with active management of the third stage of labor that was conducted at the institutional level in Guatemala in 2009. Results include details on the feasibility of introducing oxytocin in Uniject in this context as well as the acceptability of this technology among health care providers and facility managers. Available in English and Spanish.
Pilot Use of Oxytocin in a Uniject™ Device for AMTSL in Mali
This describes use of Uniject prefilled with 10 IU of oxytocin for active management of the third stage of labor in selected health centers in Mali. This study was necessary because, while Uniject had previously been used for tetanus toxoid vaccination in Mali, the Ministry of Health lacked documentation of the safety and feasibility of using Uniject to deliver oxytocin for active management of the third stage of labor.
Postpartum Hemorrhage in Thanh Hoa, Viet Nam: Assessing the Role of Active Management of Third Stage of Labor and of Oxytocin in Ampoules and Uniject Devices
PATH and the Reproductive Health Department of the Vietnam Ministry of Health, 2003
This report details findings from a study undertaken in Vietnam to evaluate the acceptability and ease of use of oxytocin in Uniject by midwives at primary- and secondary-level facilities. It also includes analyses of the effectiveness of active management of the third stage of labor (AMTSL) in reducing rates of PPH and the need for treatment of hemorrhage, the cost-effectiveness of routine delivery of AMTSL, and the relative costs of using oxytocin in ampoules or in Uniject.
These training materials may be freely used and adapted as needed for educational or noncommercial purposes, provided that the material is accompanied by an acknowledgment line. Any source files needed for adapting the materials can be made available upon request.
Using Oxytocin in the Uniject™ Injection System (10IU in 1 ml)
This job aid provides written and pictoral instruction for health workers for the administration of oxytocin in Uniject. Available in English, Spanish, and Bahasa Indonesia.
Reading Time-Temperature Indicators With the Uniject™ Injection System
This job aid illustrates how to read time-temperature indicators on Uniject. Available in English and Spanish.
Reading Time-Temperature Indicators With the Uniject™ Injection System: Worksheet
This worksheet can be used during trainings to help health workers learn how to read time-temperature indicators on Uniject. Available in English and Spanish.
Using Oxytocin in the Uniject™ Injection System for the Prevention of Postpartum Hemorrhage: A Training Presentation for Health Workers
This presentation is a basic tool for training health workers on how to use oxytocin in Uniject to prevent postpartum hemorrhage. The tool is editable so that facilitators can tailor it to their program's needs. Available in English and Spanish.
Postpartum Hemorrhage Prevention and Treatment
The Postpartum Hemorrhage Prevention and Treatment website provides a forum for information sharing and learning between organizations and individuals working on the prevention and treatment of postpartum hemorrhage in developing countries. The site contains resources posted under the Prevention of Postpartum Hemorrhage Initiative (POPPHI) and includes information and links to a range of organizations working on postpartum hemorrhage.
Visit the Postpartum Hemorrhage Prevention and Treatment website.
World Health Organization (WHO)
WHO is the directing and coordinating authority for health within the United Nations system. It is responsible for providing leadership on global health matters, shaping the health research agenda, setting norms and standards, articulating evidence-based policy options, providing technical support to countries, and monitoring and assessing health trends. The WHO website contains a wealth of information on PPH and active management of the third stage of labor including job aids, research reports, and recommended practices. Many of these documents are managed by the WHO Department of Making Pregnancy Safer.
PATH has partnered with companies in South America and Asia to manufacture oxytocin in Uniject. Oxytocin in Uniject is registered for commercial sale in Argentina, Bolivia, Guatemala, Honduras, India, and Paraguay. Applications for commercial registration in other countries in South America and Africa are currently underway.
Pilot introductions and evaluations have been conducted in Guatemala, Indonesia, Mali, and Vietnam. Additional research is being implemented in Ghana and Honduras, with interest being expressed in a number of other countries.
Now that oxytocin in Uniject is moving from development into country registration and manufacturing scale-up, more programs can now begin planning for evaluation and/or introduction activities.
PATH, through our collaboration with manufacturing partners, may be able to facilitate initial supply of oxytocin in Uniject to support country and program evaluation.
Uniject is a trademark of BD.